Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 255Rectal Neoplasms 155Colonic Neoplasms 128Stomach Neoplasms 100Pancreatic Neoplasms 94Breast Neoplasms 77Esophageal Neoplasms 76Neoplasm Metastasis 58Squamous Cell Carcinoma of Head and Neck 56Head and Neck Neoplasms 56Neoplasms 43Adenocarcinoma Of Esophagus 37Esophageal Squamous Cell Carcinoma 27Adenocarcinoma 25Unspecified Adult Solid Tumor, Protocol Specific 15Carcinoma, Hepatocellular 15Parkinson Disease 4, Autosomal Dominant Lewy Body 13Anus Neoplasms 12Keratosis, Actinic 11Gastrointestinal Neoplasms 11Biliary Tract Neoplasms 11Gallbladder Neoplasms 10Carcinoma, Squamous Cell 10Urinary Bladder Neoplasms 9Nasopharyngeal Carcinoma 9Liver Neoplasms 9Cholangiocarcinoma 9Carcinoma 9Bile Duct Neoplasms 9Recurrence 8

Interventions

napabucasin 3Irinotecan 3Gemcitabine 3Bevacizumab 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3entinostat 2Paclitaxel 2Leucovorin 2Fluorouracil 2sipuleucel-T 1pralsetinib 1pembrolizumab 1luprolide acetate gel depot 1lenvatinib 1interferon gamma-1b 1ficlatuzumab 1catumaxomab 1Vaccines 1Papillomavirus Vaccines 1Oncolytic Virotherapy 1Ocoxin 1Nivolumab 1Leuprolide 1Interferon-gamma 1Immunotherapy 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Gefitinib 1Filgrastim 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Neoplasms, Glandular and Epithelial × Fluorouracil × Clear all
NCT02753127 2023-11-15

CanStem303C

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,253 enrolled 18 charts
Gastrointestinal

Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Rectal Diseases, Colorectal Neoplasms

NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Sumitomo Pharma America, Inc.

Phase 1 Completed
7 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡